Fludarabine for the treatment of chronic lymphocytic leukaemia

Premeeting briefing

Erratum

The last sentence of paragraph 2.3.4 of the premeeting briefing for fludarabine in the treatment of chronic lymphocytic leukemia reads: “Using chlorambucil followed by fludarabine plus cyclophosphamide is, however, associated with increased toxicity, inconvenience, expense and impaired quality of life because two courses of chemotherapy are needed”. This is an error and the correct paragraph should read as follows:

2.3.4

One of the clinical specialists stated that, within the international CLL community, it has been suggested that chlorambucil should be used as the first-line treatment and that fludarabine plus cyclophosphamide should be reserved for second-line treatment. The use of fludarabine plus cyclophosphamide as a first-line treatment would reduce the treatment options for second-line therapy. Long-term disease control using chlorambucil as the first-line treatment followed by fludarabine plus cyclophosphamide is likely to be similar to first-line treatment with fludarabine plus cyclophosphamide alone. First line treatment with fludarabine plus cyclophosphamide alone is, however, associated with increased toxicity, inconvenience, expense and impaired quality of life because two courses of chemotherapy are needed.